Oramed Pharmaceuticals increased its stake in Nano Dimension to 7.2% on June 18, 2026. The shareholder formally opposed the proposed business combination with Infinite Epigenetics in a regulatory filing. Oramed is currently evaluating all available options, signaling a potential activist battle.
Nano Dimension announced a non-binding term sheet to merge with Infinite Epigenetics on June 15, 2026. The deal values the AI-powered diagnostics company at $890 million. This transaction marks a strategic pivot from digital manufacturing into healthcare AI.
Seeking Alpha downgraded Nano Dimension’s rating on June 18, 2026. The analysis labeled the $890 million acquisition as controversial.